Clinical Trials Logo

Leukemia, Myeloid, Acute clinical trials

View clinical trials related to Leukemia, Myeloid, Acute.

Filter by:

NCT ID: NCT03760666 Terminated - Clinical trials for Acute Myeloid Leukemia

A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Start date: December 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.

NCT ID: NCT03760523 Terminated - Clinical trials for Acute Myeloid Leukemia

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

Start date: April 18, 2019
Phase: Phase 1
Study type: Interventional

This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)

NCT ID: NCT03760445 Withdrawn - Clinical trials for Leukemia, Myeloid, Acute

HDM201 Added to CT in R/R or Newly Diagnosed AML

Start date: November 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center open-label Phase I/II study investigating orally administered HDM201 in combination with chemotherapy in two populations: subjects with first line AML or subjects with relapsed/refractory AML. This study is conducted in three parts: dose escalation, dose expansion and DDI study.

NCT ID: NCT03760237 Completed - Clinical trials for Leukemia, Myeloid, Acute

Cardiovascular Function in Acute Leukemia

Start date: December 10, 2018
Phase:
Study type: Observational [Patient Registry]

An observational, prospective study to describe the rates and predictors of cardiovascular events in patients with acute leukemia.

NCT ID: NCT03755856 Recruiting - Clinical trials for Acute Myeloid Leukemia

Long-term Outcomes for Acute Myeloid Leukemia Patients

1621-QLG-LG
Start date: May 16, 2019
Phase:
Study type: Observational

This international observational study aims at examining the patterns of health-related quality of life differences between long-term acute myeloid leukemia patients and their healthy peers from the general population.

NCT ID: NCT03755414 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Start date: September 4, 2019
Phase: Phase 1
Study type: Interventional

In this trial, the investigators will begin to explore the possibility that, as in mice, janus kinase inhibitor 1 (JAK1) inhibition with haploidentical-hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) and cytokine release syndrome (CRS) while retaining Graft-versus-Leukemia (GVL) and improving engraftment. The purpose of this pilot study is to determine the safety of itacitinib with haplo-hematopoietic cell transplantation (HCT) measured by the effect on engraftment and grade III-IV GVHD.

NCT ID: NCT03755154 Completed - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Start date: July 17, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this first in human study is to assess safety, tolerability, Pharmacokinetic (PK) and preliminary clinical activity and to estimate the Maximum Tolerated Doses (MTD(s))/ Recommended Phase 2 Doses (RP2D(s)) of S65487 as single agent administered intravenously (i.v.) in adult patients with refractory or relapsed Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) or Chronic Lymphocytic Leukemia (CLL).

NCT ID: NCT03752138 Withdrawn - Clinical trials for Refractory Acute Myeloid Leukemia

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Start date: March 31, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of TK216 and decitabine when given together in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as TK216 and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03747757 Active, not recruiting - Lymphoma Clinical Trials

Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue

Start date: November 29, 2018
Phase: Phase 2
Study type: Interventional

This trial studies how well cognitive behavioral therapy works in helping patients with acute myeloid leukemia or lymphoma with cancer-related fatigue. Behavioral therapy uses methods to help patients change the way they think and act. Behavioral skills may help patients with acute myeloid leukemia or lymphoma cope with anxiety, depression, and other factors that may influence their level of cancer-related fatigue.

NCT ID: NCT03746912 No longer available - Clinical trials for Acute Myeloid Leukemia With Gene Mutations

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Start date: n/a
Phase:
Study type: Expanded Access

An expanded access program (EAP): - Allows doctors to give medicine to patients, - Before it is approved by health authorities. This EAP is for: - Quizartinib - Patients with FLT3-ITD mutated AML, - AML that has come back, or - Is resistant to other therapies. A participant will receive quizartinib if: - The doctor submits a request, - The participant is eligible, and - The country allows the EAP.